Pharmaline has been acquired by Gilde Healthcare Partners
The private shareholders of Pharmaline have sold 55% of their share capital to Gilde Healthcare Partners for an undisclosed consideration.
Pharmaline is specialized in the semi-industrial manufacturing of unregistered pharmacy preparation products. Pharmaline's facilities and production processes are structured to comply with the guidelines of the Dutch Health Care Inspectorate and the Good Manufacturing Practice guidelines, which have been mandatory for a pharmacy preparation production company since 2007. Pharmaline services the Dutch intramural (hospital pharmacies) and extramural (public pharmacies and general practitioner’s pharmacies) pharmacy markets.
Gilde Healthcare Partners is a European venture capital and growth capital firm. The funds focus on companies engaged in the development of novel therapeutics, diagnostics, medical devices and healthcare services.
Oaklins' team in the Netherlands acted as advisor to the seller in this transaction.
Talk to the deal team
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreMark Climate Technology has acquired Heber GmbH
Heber GmbH has been acquired by Mark Climate Technology, a specialist in climate control systems and a portfolio company of Bolster Investment Partners. This partnership strengthens the positions of both companies in the global market for innovative and sustainable climate solutions, as well as creating unique synergies. Mark Climate's expertise in standardized, scalable solutions is enhanced by Heber's emphasis on customer-specific customization.
Learn moreGrupo Veta 2017 S.L. has been acquired by MSA Mizar
The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.
Learn more